NCT07479979 2026-03-18
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Not yet recruiting
Clinical Trials
16 trialsNCT07082270 2026-02-19
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07334535 2026-01-13
Isa-VRD in TIE HRMM
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
NCT07335887 2026-01-13
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT07301138 2025-12-24
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
Phase 2 Not yet recruiting
NCT07285239 2025-12-16
PrE1005
PrECOG, LLC.
Phase 3 Not yet recruiting
NCT07254416 2025-11-28
A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 4 Not yet recruiting
NCT07227584 2025-11-12
ALL Backbone in AYAs
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT07032714 2025-06-26
MAGENTA
Massachusetts General Hospital
Phase 1 Not yet recruiting
NCT07015021 2025-06-11
DKPD
The First Affiliated Hospital of Soochow University
Phase NA Not yet recruiting
NCT06643689 2024-11-14
TAPES
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT06300099 2024-03-12
Dexamethasone Versus Dexmedetomidine as Adjuncts to Serratus Anterior Plane Block
Al-Azhar University
Phase 4 Not yet recruiting
NCT05909826 2023-06-18
KMM-KCd
Dong-A University Hospital
Phase 2 Not yet recruiting
NCT05581875 2022-10-17
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
Hellenic Society of Hematology
Phase 1/2 Not yet recruiting
NCT05527340 2022-09-02
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
PETHEMA Foundation
Phase 2 Not yet recruiting